Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Medica
Melanoma, BRAF V600 mutation-positive unresectable or metastatic
Initial criteria
- age ≥ 18 years
- BRAF V600 mutation-positive disease
- used in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib)
- prescribed by or in consultation with an oncologist
Approval duration
1 year